  |
 | Up a level |
Paz-Ares, L. and Chen, Y. and Reinmuth, N. and Hotta, K. and Trukhin, D. and Statsenko, G. and Hochmair, M. J. and Özgüroglu, M. and Ji, J.H. and Garassino, M. C. and Voitko, O. and Poltoratskiy, A. and Musso, E. and Havel, L. and Bondarenko, I. and Losonczy, G. and Conev, N. and Mann, H. and Dalvi, T. B. and Jiang, H. and Goldman, J. W. (2022) Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open, Vol. 7 (no. 2). p. 100408. ISSN 2059-7029 (Online)
Zhang, Q. and Xu, B. and Zhang, Q. and Sun, T. and Li, W. and Teng, Y. and Hu, X. and Bondarenko, I. and Adamchuk, H. and Zhang, L. and Trukhin, D. and Wang, S. and Zheng, H. and Tong, Z. and Zhang, X. and Liu, E. and Jiang, W. and Liu, S. and Luk, A. (2018) Global clinical trials validating bioequivalence with China-manufactured trastuzumab biosimilar, HLX02, and trastuzumab. Annals of Oncology, Vol.29 (Supp.9). ix16. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
